Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.
Medications Sep 05, 2011 | 5 / 5 (4) | 1
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting ...
Medications Mar 05, 2013 | 5 / 5 (4) | 3
The substitution of brand-name antiepileptic drugs with cheaper generic equivalents has been an ongoing point of contention among doctors, federal officials and people with epilepsy.
Medications Feb 17, 2012 | 5 / 5 (2) | 0 |
(AP) -- A pill developed in Bulgaria during the Soviet era shows promise for helping millions of smokers cheaply and safely kick the habit, the first big study of it shows.
Health Sep 28, 2011 | 4.5 / 5 (2) | 0
(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.
Medications Oct 24, 2011 | 3 / 5 (2) | 0
Indian pharmaceutical giant Ranbaxy won US regulatory approval to make the first generic version of cholesterol lowering drug Lipitor, a Pfizer product whose patent expired Wednesday.
Medications Dec 01, 2011 | 5 / 5 (1) | 0
The US Supreme Court ruled Tuesday that generic drug makers can challenge big-name pharmaceutical firms in court to stop them from broadening the scope of their patent descriptions.
Medications Apr 18, 2012 | 5 / 5 (1) | 0
(AP)—Teva Pharmaceuticals has stopped shipping its generic version of a popular antidepressant off the market after a U.S. government analysis showed the pill does not work properly.
Medications Oct 03, 2012 | 5 / 5 (1) | 0
Despite U.S. Food and Drug Administration regulations requiring generic medications to carry identical warnings to those on corresponding brand-name products, a study by Regenstrief Institute researchers has found that more ...
Medications Dec 13, 2012 | 5 / 5 (1) | 0